Actively Recruiting
Study of BRS201 Drug Treatment for Adults with Primary Sclerosing Cholangitis A Randomized, Double-Blind Crossover Trial with Oral and IV Medication
Led by Brigham and Women's Hospital · Updated on 2026-07-21
28
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of the drug BRS201 hydroxocobalamin as a treatment for patients with primary sclerosing cholangitis PSC, a liver condition. This Phase 2 clinical trial uses a randomized, quadruple-blind, crossover design to compare BRS201 to a placebo. The study aims to measure how the drug affects alkaline phosphatase ALP levels, an important marker in PSC. Participants will undergo four weeks of treatment with BRS201 followed by four weeks of placebo, or vice versa, taking oral medication twice daily. Some participants may also receive a one-time intravenous dose of BRS201 before the oral treatment. The trial includes different dosage groups and a possible repeat phase for the most effective treatment. Participants will attend nine remote study visits over eight weeks. They will take the study medication, track adherence in a log, and provide blood and stool samples for laboratory tests. A research nurse will visit participants at home to collect samples, making participation more convenient. The study monitors ALP levels to assess treatment response and safety throughout the trial.
CONDITIONS
Brief Title
Detoxification of the Liver In PSC (Dolphin)
Research Team
S
Sophie Mitchell, BS
S
Siani Ellis, BS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here